newsfilter
← Latest News
PR Newswire·

TC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder Update

Dosed first three patients within Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia (AML).Complete and near complete responses (morphologic